Pharmacokinetics of MB-102 and Use of the Non-invasive Optical Renal Function Monitor (ORFM) Device in Subjects With Normal and Impaired Renal Function and a Range of Skin Color Types

NCT02772276 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

234

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Kidney Injury

Interventions

DRUG: MB-102-- single dose of 4 µmol/kg
DRUG: MB-102-- single dose of 130 mg
DRUG: MB-102-single dose of 130 mg or 2 doses of 130 mg 12 hours apart
DRUG: MB-102-- two doses of 130 mg 24 hours apart
DRUG: Iohexol
DEVICE: QuantumLeap
DEVICE: Radiance
DEVICE: Brilliance (1 or 2 sensors)
DEVICE: Brilliance (2-part sensor)

Sponsor

MediBeacon